Faster ulcer healing indicated in results of amniotic membrane allograft study

A study by Skye® Biologics El Segundo, CA, USA) has indicated a 98% complete wound healing rate in ulcer patients within 12 weeks of using WoundEx® FastActing Membrane, a dehydrated human amniotic membrane allograft aimed at treating chronic diabetic foot and venous leg ulcers.

Go to the profile of RegMedNet
Nov 17, 2016

A pilot study investigating the use of Skye® Biologics’ (El Segundo, CA, USA) proprietary dehydrated human amniotic membrane tissue allograft for the treatment of lower extremity wounds has indicated that the WoundEx® FastActing Membrane™ results in accelerated healing in diabetic foot and venous leg ulcers. The company has announced that the study has shown a 98% complete wound heal rate within 12 weeks.

The US healthcare system reports that refractory nonhealing wounds are a significant burden. Diabetic foot ulcers are the main cause of nontraumatic lower extremity amputation and in 2012 cost the USA US$245 billion. Venous leg ulcers are even more common and affect over 2 million individuals each year. Standard treatments for these wound types include debridement, collagens and pressure relief, to name a few.

The study, led by Dr Eric Lullove of the West Boca Center for Wound Healing (FL, USA), included 20 male and female patients with chronic nonhealing wounds that had a larger than average wound size. They were treated using conventional methods initially to clear the wound of bioburden, with WoundEx application at weeks 1, 3 and 5, if needed. Reduction in wound size with WoundEx treatment was seen in 46% of patients at 4 weeks, with 98% wound closure recorded at 12 weeks.

The FastActing WoundEx Amniotic Membrane is described as a skin substitute formulated using next-generation scientific methods to support tissue reformulation while keeping pain and inflammation in check and reducing scarring. Lullove elaborates: “it performs remarkably well to advance and progress these wounds to healing. I have used various types of tissue biologics in my practice, and this is now my go-to tissue for advanced wound healing.”

It is hoped that technologies such as this will enable patients with chronic diabetic and venous ulcers to have a better chance at more efficient wound healing in conjunction with traditional techniques.

Note, at the time of writing, the results of the study, indicated as a peer-reviewed pilot study, were on file.

– Written By Zara Parker

Source: Skye® Biologics Announces WoundEx® Membrane Recent Study Reveals Accelerated Wound Closure Rates:

Go to the profile of RegMedNet


eCommunity, Future Science Group

RegMedNet is a networking site where users can share their knowledge and insights. This profile will share some content and updates from the RegMedNet team, including webinars, news and journal articles.

No comments yet.